• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    U

    University Hospital (London, Ontario)

    9,075论文总数
    29万引用总数

    University Hospital is a large teaching hospital in London, Ontario, Canada, that is affiliated with the University of Western Ontario's Schulich School of Medicine & Dentistry. It is part of the London Health Sciences Centre hospital network and the Lawson Health Research Institute, which manages clinical research across all London hospitals. The hospital was formally opened in September 1972 by Canadian neurosurgeon Wilder Penfield.Neurosurgeon Charles Drake achieved international renown for his innovative surgery for brain aneurysms at University Hospital, which attracted patients and surgeons from around the world to London.

    论文量&引用量时间轴

    机构学者

    论文(9075)

    年份
    起
    –
    止
    排序
    1Development and Psychometric Validation of the Chronic Rhinosinusitis Control Test.
    R A Cotter, C W Lee, K Wilson, S F Althoff, S Alsaleh, W T Anselmo-Lima, M Bernal-Sprekelsen, R K Chandra, J Constantinidis, W J Fokkens, A, T Herzog,

    BACKGROUND:Disease control assessment for chronic rhinosinusitis (CRS) remains a challenge. In this study, we develop and psychometrically validate a new patient-reported outcome measure, the Chronic Rhinosinusitis Control Test (CRCT), for assessing CRS control. METHODOLOGY:The CRCT, which includes 8 items and has a score that ranges from 0-31, incorporates the perspectives of key stakeholders (patients and healthcare providers) and was developed incorporating methodologic guidance from the COSMIN initiative and United States Food and Drug Administration. Psychometric validation was performed in line with recommendations from the COSMIN initiative to establish validity, reliability and responsiveness in a sample of 545 CRS patients and with the participation of 23 expert rhinologists. RESULTS:The CRCT has excellent face validity, content validity, concurrent validity, internal consistency, test-retest reliability, and responsiveness. Factor analysis reveals that the CRCT has 2 subdomains: sinonasal and impairment subdomains in addition to a final item related to CRS-related oral corticosteroid usage in the past 3 months. Using a distribution-based and multiple anchorbased methods, the CRCT has a minimal clinically important difference (MCID) of 4 points. After 23 expert rhinologists independently classified all possible combinations of scoring on the CRCT, scores of ≤7 indicate controlled CRS, 8 to 15 (inclusive) partly controlled CRS and ≥16 uncontrolled CRS. CONCLUSION:The CRCT is a psychometrically validated measure of CRS control. CRS may be classified as controlled based on CRCT score ≤7, partly controlled with CRCT score of 8 to 15 (inclusive) and uncontrolled with CRCT score ≥16. The MCIDs for improvement and worsening are both 4.

    2026Rhinology(2026)引用:4
    引用
    AI阅读
    加入学术空间
    2Substantially Fewer Lung Cancer Diagnoses During Breast Cancer Follow Up after Targeted Intraoperative Radiotherapy Compared with Whole External Beam Breast Radiotherapy in the TARGIT-A Randomised Trial: a 25-Year Update
    Jayant S. Vaidya, Norman R. Williams,Max Bulsara,Michael Baum,Chris Brew-Graves,Ingrid Potyka, Nicholas J. Roberts, Julie Lindsay,Siobhan Laws, Sanjay Raj,Michael Douek,Mary Falzon,
    2026European Journal of Surgical Oncology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Clinical Features and Treatment Outcomes of POEMS-associated Castleman Disease.
    Grace Lau, Victor Jia Wei Zhang, Zara Markovic-Obiago,Oliver Tomkins,Simon Wan,Satyen H Gohil,Shirley D'Sa, Michael P Lunn,Jonathan Sive
    2026British journal of haematology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    4Multimodality Curative-Intent Treatment in NSCLC: an Unprecedented Era of Change 2017-2025.
    Matthew Evison, Tanya Ahmed, Meenali Chitnis, Rebecca Ward, Daniel Netto,Laura Cove-Smith,Riyaz Shah,Nicola Steele, Gerard Walls, Doug West,Neal Navani

    Curative-intent multimodality treatment-combining local treatments such as surgery or radiotherapy with systemic therapy-is the cornerstone of care in stage II-III non-small cell lung cancer (NSCLC). Since 2017, the systemic therapy backbones with multimodality treatment have undergone a dramatic transformation, driven by a series of pivotal, practice-changing clinical trials. Immunotherapy and targeted therapies, previously confined to the advanced/metastatic setting, are now firmly embedded in curative-intent regimens. Maintenance immunotherapy following chemoradiation in unresectable stage III disease, adjuvant tyrosine kinase inhibitors in resected epidermal growth factor receptor/anaplastic lymphoma kinase-positive tumours, neoadjuvant and perioperative chemoimmunotherapy in resectable stage II/III NSCLC and adjuvant chemoimmunotherapy following resection have all become new standards of care.This state-of-the-art review synthesises the key evidence underpinning these developments, highlights their clinical implications and identifies challenges to implementation-particularly the need for redefined clinical pathways, accurate pretreatment staging, timely biomarker testing and coordinated multidisciplinary decision-making. A novel treatment algorithm is proposed to support clinicians in navigating these complex treatment choices.We conclude that immunotherapy and targeted agents have irrevocably altered curative-intent NSCLC care, establishing multiple new standards that sometimes overlap and compete. In the surgical multimodality treatment pathway, neoadjuvant and perioperative chemoimmunotherapy offers the opportunity to increase the uptake of systemic therapy in comparison to adjuvant therapy and is considered by these authors to represent the optimal treatment path for most patients.In this unprecedented era of therapeutic expansion, the greatest challenge is no longer the absence of effective treatments, but the complexity of selecting, sequencing and delivering them, as well as patient optimisation. Lung cancer services must evolve through proactive pathway redesign, integrated diagnostics and new models of multidisciplinary care. High-quality, biomarker-driven and patient-centred care is now achievable for many patients with stage II-III NSCLC-but it will require system-level adaptation to deliver it.

    2026Thorax(2026)引用:2
    引用
    AI阅读
    加入学术空间
    5MONOGERM, A NOVEL PROOF-OF-PRINCIPLE BAYESIAN PHASE II TRIAL DESIGN OF CARBOPLATIN OR VINBLASTINE MONOTHERAPY INDUCTION PRIOR TO RADIOTHERAPY FOR INTRACRANIAL GERMINOMA
    L. Kirton,J. R. Apps,A. Lawson, T. Arvanitis,D. Mitra, R. Gagen, H. Patel,A. Peet,L. Fern, E. Williams,N. Coleman,T. Ajithkumar,

    Abstract BACKGROUND Current European standard-of-care for localised intracranial germinoma is multi-agent chemotherapy (carboPEI: carboplatin/etoposide/ifosfamide) followed by definitive radiotherapy, with excellent survival. MonoGerm is a de-escalation, non-inferiority trial aiming to reduce toxicity. Twelve-week carboplatin (PMID:8039122) AUC10 or vinblastine (PMIDs:32642701/34520101) induction will be evaluated to test if as effective as carboPEI from SIOP-CNS-GCT-II. A novel trial design was required to answer this question pragmatically/safely. METHODS Clinical trials in rare diseases recruit slowly, allowing continuous monitoring of efficacy outcomes. Efficacy-transition-pathways (ETP) are innovative visual tools to aid determination of trial design parameters, and an extension of the dose-transition-pathways concept introduced for dose-finding trials (PMID:28733440). RESULTS MonoGerm includes two monotherapies, with each single arm recruiting six cohorts of three patients, with interim assessment after each recruited cohort and final analysis at 18 patients (total n=36). Insufficient tumour volume response (<30%) at 6-week safety MRI results in 12-weeks carboPEI. Primary outcome is radiological complete response (CR) by 12-weeks of induction monotherapy. A beta-binomial conjugate analysis will generate posterior probability distributions, combining observed trial data as realisations from a binomial distribution with a minimally informative Beta (1,1) prior. Decision criteria to allow early stopping at interim analyses and go/no-go decisions at final analysis are based on probabilities from these posterior distributions. ETP visually maps out parameters used to assert decisions after each interim assessment as a pyramid decision tree. For each recruited cohort and every CR outcome, estimates of the true CR rate and probabilities with associated decisions are mapped out. ETP allows clear communication between statisticians, clinicians, and patient-public-involvement (PPI) teams, facilitating informed decisions in an efficient/realistic trial design. CONCLUSION MonoGerm, a novel Bayesian de-escalation trial, funded by Little Princess Trust (https://www.littleprincesses.org.uk/), uses ETP and continuous monitoring with built-in stopping rules to ensure patient safety in this treatment de-escalation trial.

    2026CLINICAL ONCOLOGY(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 9075 篇论文

    合作机构(100)

    卢旺天主教大学合作论文 884
    伦敦大学学院合作论文 284
    伦敦玛丽女王大学合作论文 184
    帝国理工学院合作论文 165
    牛津大学合作论文 164
    国王大学合作论文 144
    伦敦大学学院医院 NHS 基金会信托合作论文 135
    皇家自由医院合作论文 122
    伦敦皇家医院合作论文 117
    曼彻斯特大学合作论文 114

    机构统计